Results from the pivotal phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival (PFS), compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (median PFS, 95% CI (19.3 months – not reached) vs 14.7 months (13.0 – 16.5 months); HR=0.556; p=0.00000329.
UC Davis Health and UCLA are co-leading a newly funded national clinical trial to evaluate whether AI can help radiologists interpret screening mammograms more accurately. The goal is to improve breast cancer detection and reduce unnecessary callbacks and anxiety for patients.
